Inhibrx Biosciences, Inc.
INBX
$82.96
$0.710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -155.09M | -163.69M | 1.72B | 1.69B | 1.64B |
| Total Depreciation and Amortization | 2.61M | 2.79M | 2.60M | 2.29M | 1.89M |
| Total Amortization of Deferred Charges | 1.80M | 1.16M | 1.36M | 2.07M | 3.31M |
| Total Other Non-Cash Items | 13.18M | 13.01M | -1.94B | -1.94B | -1.93B |
| Change in Net Operating Assets | -5.90M | 6.89M | 48.18M | 52.05M | 80.40M |
| Cash from Operations | -143.39M | -139.85M | -167.25M | -194.41M | -207.51M |
| Capital Expenditure | -47.00K | -284.00K | -1.50M | -2.60M | -6.02M |
| Sale of Property, Plant, and Equipment | 3.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -44.00K | -284.00K | -1.50M | -2.60M | -6.02M |
| Total Debt Issued | 99.97M | 99.97M | 99.97M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 352.00K | 0.00 | 32.95M | 71.68M | 72.76M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -125.00K | -125.00K | -125.00K | -- | -225.00K |
| Cash from Financing | 100.19M | 99.84M | 132.79M | 71.68M | 72.54M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.24M | -40.29M | -35.96M | -125.33M | -141.00M |